Scilex is distributing roughly 10.7 million Semnur shares to its stockholders — out of approximately 186 million Semnur shares it currently holds. That ratio tells you everything about the strategic intent here: this is not a divestiture. Scilex retains an overwhelming majority stake in Semnur after the dividend, which means the spin-out dynamic is mostly optics. What the structure actually accomplishes is giving Semnur a public shareholder base on the OTC market while keeping operational and financial control firmly inside Scilex.
The mechanics are a 1-for-1 share dividend against Scilex common stock, with a record date of June 1, 2026, and a payment window within 60 days of that date. The board retains the right to revoke or reschedule before the payment date — an unusual carve-out that signals the transaction is still contingent on solvency and surplus conditions holding. That’s a real qualifier, not boilerplate. Scilex is a small-cap carrying commercial products like ZTlido and ELYXYB alongside a pipeline that hasn’t crossed the finish line, and the solvency language suggests the board is being deliberate about liability exposure before completing the transfer.
Semnur’s core asset is SP-102 (SEMDEXA), a dexamethasone viscous gel for epidural injection in sciatica that completed Phase 3 and has FDA Fast Track designation — but has not received approval. That’s a late-stage asset with real unmet need sitting in an awkward middle state: derisked enough to spin into a separately traded entity, not derisked enough to command obvious commercial partnership terms. Giving Semnur its own stock and shareholder base creates the infrastructure for Semnur to pursue independent financing or a partnership without Scilex’s balance sheet constraints complicating negotiations.
The one number to watch is how much of the 186 million Semnur shares Scilex eventually parts with beyond the initial 10.7 million. That figure — the pace and scale of further secondary distributions or sales — will determine whether Semnur becomes a genuinely independent company pursuing SEMDEXA’s approval on its own terms, or whether this dividend is a capital markets maneuver that leaves Semnur permanently tethered to its parent’s fortunes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
